GSK
GSK
779 hedge funds and large institutions have $9.91B invested in GSK in 2017 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 282 increasing their positions, 267 reducing their positions, and 58 closing their positions.
97% more call options, than puts
Call options by funds: $142M | Put options by funds: $72.1M
6% more capital invested
Capital invested by funds: $9.34B → $9.91B (+$569M)
6% more repeat investments, than reductions
Existing positions increased: 282 | Existing positions reduced: 267
5% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 58
0.14% more ownership
Funds ownership: 3.6% → 3.74% (+0.14%)
0% more funds holding in top 10
Funds holding in top 10: 11 → 11 (0)
1% less funds holding
Funds holding: 787 → 779 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$211M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$118M |
| 3 |
Millennium Management
New York
|
+$98.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$59.2M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$35.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$248M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$84.5M |
| 3 |
MHI
Miller Howard Investments
Kingston,
New York
|
-$22.2M |
| 4 |
Goldman Sachs
New York
|
-$19.7M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$14.9M |
GSK Hedge Fund Activity: Q2 2017 in Review
779 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q2 2017, worth a combined $9.91B — up 6.1% from $9.34B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new GSK positions and 58 closed out — a net gain of 3 holders — while 282 added to existing stakes and 267 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $211M. The largest seller was Arrowstreet Capital, cutting an estimated $248M.
- 779 institutional investors held GSK (GSK) as of Q2 2017, down from 787 in Q1 2017.
- Funds reported $9.91B of GSK stock for Q2 2017, up 6.1% quarter-over-quarter.
- 61 funds opened new GSK positions in Q2 2017 and 58 closed out, a net change of +3 holders.
- The largest GSK buyer in Q2 2017 was Renaissance Technologies, an estimated $211M added.
- The largest GSK seller in Q2 2017 was Arrowstreet Capital, an estimated $248M sold.
Based on aggregated 13F filings for Q2 2017.